Pfizer Inc (PFE)

PFE (NYSE:Drugs) EQUITY
$32.80
pos +0.09
+0.28%
Today's Range: 32.50 - 33.00 | PFE Avg Daily Volume: 49,137,100
Last Update: 05/02/16 - 4:01 PM EDT
Volume: 38,060,808
YTD Performance: 0.00%
Open: $32.56
Previous Close: $32.71
52 Week Range: $28.25 - $36.46
Oustanding Shares: 6,184,139,991
Market Cap: 203,520,047,104
6-Month Chart
TheStreet Ratings Grade for PFE
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 8 7 7 8
Moderate Buy 0 0 0 1
Hold 5 3 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.77 1.60 1.60 1.54
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 0.00
Price Earnings Comparisons:
PFE Sector Avg. S&P 500
0.00 29.60 12.90
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
0.00% 0.00% 0.00%
GROWTH 12 Mo 3 Yr CAGR
Revenue -1.50 -0.20 -0.06
Net Income -23.80 -0.30 -0.10
EPS -21.70 -0.40 -0.17
Earnings for PFE:
EBITDA 18.13B
Revenue 48.85B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $0.55 $0.58 $2.29 $2.54
Number of Analysts 9 6 10 9
High Estimate $0.56 $0.60 $2.33 $2.69
Low Estimate $0.53 $0.56 $2.26 $2.34
Prior Year $0.51 $0.56 $2.20 $2.29
Growth Rate (Year over Year) 7.19% 4.46% 4.27% 10.53%
Chart Benchmark
Average Frequency Timeframe
Indicator Chart Scale  
Symbol Comparison Bollinger Bands

updatePFE Investor Mtg.

Apr 28, 2016 | 7:02 AM EDT

PFE - Pfizer Inc Annual Shareholders Meeting - 8:30AM

By

Bret Jensen

 | Apr 18, 2016 | 12:30 PM EDT

After the thwarted Pfizer merger, the generic drug business sale will supply plenty of "ammo."

By

Bret Jensen

 | Apr 18, 2016 | 10:00 AM EDT

After the thwarted Pfizer merger, the generic drug business sale will supply plenty of "ammo."

By

Doug Kass

 | Apr 18, 2016 | 9:37 AM EDT
Continuing loan-loss-provision increases. Difficult capital markets (i.e., slow transaction activity and a weak IPO market). Softer merger-and-acquisition activity, hurt by political and geopolitical events, as well as the Justice Department's recent actions against
By

Bret Jensen

 | Apr 15, 2016 | 8:30 AM EDT

The oversold biotech sector is recovering.

By

Bret Jensen

 | Apr 14, 2016 | 11:00 AM EDT

Pharma and biotech giants now must look to small- and mid-caps to fill out pipelines and bolster growth.

By

Jim Cramer

 | Apr 13, 2016 | 1:25 PM EDT

Pfizer walked away from Allergan and the stock has acted better, said TheStreet's Jim Cramer.

By

Jim Cramer

 | Apr 13, 2016 | 11:35 AM EDT

Jim Cramer says he continues to worry about Valeant and he’s racking his brain trying to figure out how much the company’s shares are worth.

By

James Passeri

 | Apr 12, 2016 | 12:32 PM EDT

Billionaire Bill Ackman's recent appointment to the troubled drugmaker's board could signal a meanful change of direction.

By

Jim Cramer

 | Apr 11, 2016 | 11:16 AM EDT

Jim Cramer says the antitrust environment out there will make it difficult for any railroad mergers to be approved by regulators.

My last NFLX zone did not hold and it did not trigger. This new zone however is holding a...
Even though I have timing at this last low in SPX cash and futures, since the S&P decl...
That could put an axe into the stock here near 30x forward earnings.  Comps were OK t...
CIRCOR International (CIR) ripping into the close on a basic upgrade.  The stock has ...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.